Pfizer Inc. (PFE) and LianBio (LIAN0 announced that Pfizer opted in to the right to develop and commercialize sisunatovir, a respiratory syncytial virus therapeutic candidate, in Mainland China, Hong Kong, Macau, and Singapore pursuant to the companies’ existing strategic collaboration to expand patient access to novel therapeutics in Greater China. Sisunatovir is an investigational, orally administered fusion inhibitor designed to block RSV replication by inhibiting F-mediated fusion with the host cell. Sisunatovir is being evaluated for the potential treatment of RSV infection in pediatric and adult patients. In June 2022, Pfizer acquired ReViral Ltd. and its portfolio of RSV therapeutic candidates with the exception of development and commercialization rights for sisunatovir in Mainland China, Hong Kong, Macau, and Singapore, which LianBio had previously in-licensed from ReViral in March 2021. Under the terms of Pfizer’s opt-in to sisunatovir rights, LianBio will receive a $20 million upfront payment, to be released from previously restricted cash paid by Pfizer to LianBio in 2020 under the companies’ existing strategic collaboration. Additionally, LianBio is eligible to receive up to $135 million in potential development and commercial milestone payments and tiered low single digit percent of sisunatovir net sales in the territories. Pfizer will assume all development and commercial activities and costs in the region and will release LianBio from its royalty and milestone obligations for sisunatovir.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
- Pfizer to provide U.S. Government with added 3.7M courses of Paxlovid
- Warren, Welch tell Pfizer to ‘back off’ price hike for vaccine, STATNews says
- Roche announces collaboration with Pfizer to help patients positive for COVID-19
- Pfizer awarded $1.96B Army contract modification for Paxlovid